Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia

Jennifer K. Long, Toni K. Choueiri, Geraldine S. Hall, Robin K. Avery, Mikkael A. Sekeres

Research output: Contribution to journalArticle

Abstract

Daptomycin is a lipopeptide antimicrobial used for the treatment of aerobic gram-positive skin and soft tissue infections. We describe a patient with acute myeloid leukemia whose febrile neutropenia was treated with daptomycin and who later developed daptomycin-resistant Enterococcus faecium infection. Defervescence and negative blood cultures ensued after treatment with linezolid. Guidelines for testing daptomycin susceptibilities of enterococci include breakpoints only for vancomycin-susceptible Enterococcus faecalis, making interpretation of minimum inhibitory concentrations for common clinical infections difficult. No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives.

Original languageEnglish (US)
Pages (from-to)1215-1216
Number of pages2
JournalMayo Clinic proceedings
Volume80
Issue number9
DOIs
StatePublished - Sep 2005
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this